385 related articles for article (PubMed ID: 1682039)
1. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
[TBL] [Abstract][Full Text] [Related]
4. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Groot K; Halmos G
Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
[TBL] [Abstract][Full Text] [Related]
5. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
Zalatnai A; Schally AV
Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
Radulovic S; Miller G; Schally AV
Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
[TBL] [Abstract][Full Text] [Related]
7. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Qin Y; Ertl T; Cai RZ; Halmos G; Schally AV
Cancer Res; 1994 Feb; 54(4):1035-41. PubMed ID: 8313359
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
Szepshazi K; Halmos G; Groot K; Schally AV
Int J Pancreatol; 1994; 16(2-3):141-9. PubMed ID: 7868940
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally AV
Int J Cancer; 1994 May; 57(4):574-80. PubMed ID: 7910153
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging.
Qin Y; Van Cauteren M; Osteaux M; Schally AV; Willems G
Cancer Res; 1992 Nov; 52(21):6025-30. PubMed ID: 1356623
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
Szepesházi K; Halmos G; Schally AV; Arencibia JM; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
[TBL] [Abstract][Full Text] [Related]
16. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
Szepeshazi K; Lapis K; Schally AV
Int J Cancer; 1991 Sep; 49(2):260-6. PubMed ID: 1679045
[TBL] [Abstract][Full Text] [Related]
17. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
Paz-Bouza JI; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
Szende B; Srkalovic G; Schally AV; Lapis K; Groot K
Cancer; 1990 May; 65(10):2279-90. PubMed ID: 1971771
[TBL] [Abstract][Full Text] [Related]
19. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
[TBL] [Abstract][Full Text] [Related]
20. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Pinski J; Halmos G; Szepeshazi K; Schally AV
Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
